[^1]
| Gene |
[ATXN2](/genes/atxn2) |
| UniProt |
Q99700 |
| PDB |
No structures deposited |
| Mol. Weight |
140 kDa (1313 aa) |
| Localization |
Cytoplasm, stress granules, RNA processing bodies (P-bodies) |
| Family |
Ataxin-2 family, RNA-binding proteins |
| Diseases |
[Spinocerebellar Ataxia Type 2 (SCA2)](/diseases/spinocerebellar-ataxia-type-2), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), [Parkinson's Disease](/diseases/parkinsons-disease) |
Ataxin-2 is a cytoplasmic RNA-binding protein encoded by the ATXN2 gene that plays critical roles in RNA metabolism, stress granule dynamics, and translational control. Originally identified for its role in spinocerebellar ataxia type 2 (SCA2), ataxin-2 has emerged as a major player in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease through its interactions with stress granules, RNA metabolism, and the C9orf72 hexanucleotide repeat expansion.
Ataxin-2 is a large 1313-amino acid protein with multiple functional domains:
- N-terminal region (aa 1-200): Contains the PAM2 motif for PABP binding
- Lsm domain (aa 250-350): RNA-binding module
- Moter domain (aa 400-600): Mediates protein-protein interactions
- Polyglutamine (polyQ) tract (aa ~800-900): Normal: 22-33 glutamines; Pathogenic: >34 (SCA2)
- C-terminal region (aa 900-1313): Contains multiple RNA recognition motifs (RRMs) and a prion-like domain
The protein contains multiple Lsm (Like-Sm) and PAM2 motifs that mediate interactions with RNA processing machinery and poly(A)-binding protein (PABP).
Under physiological conditions, ataxin-2 performs essential functions in RNA metabolism:
- RNA splicing regulation
- mRNA translation control
- mRNA stability and decay
- MicroRNA (miRNA) processing
Ataxin-2 localizes to stress granules (SGs) and processing bodies (P-bodies) in response to cellular stress:
- Regulates SG assembly and disassembly
- Coordinates mRNA triage between translation and degradation
- Links stress response to translational control
- Interacts with PABP to regulate poly(A)-tail metabolism
- Modulates ribosome activity
- Controls selective mRNA translation during stress
Ataxin-2 with expanded polyglutamine tracts causes spinocerebellar ataxia type 2 (SCA2):
- Normal polyQ length: 22-33 repeats
- Pathogenic range: 34-200+ repeats
- Age of onset: Inversely correlates with repeat length
- Penetrance: Nearly complete for repeats >47
The expanded polyQ tract leads to:
- Toxic gain-of-function: Aberrant protein interactions
- Aggregate formation: Intranuclear inclusions
- Transcriptional disruption: Altered gene expression
- RNA metabolism defects: Dysregulated mRNA processing
- Calcium dysregulation: Channel and signaling abnormalities
Ataxin-2 intermediate polyQ expansions (27-33 repeats) are an ALS risk factor:
- Found in 4-5% of sporadic ALS cases
- Associated with faster disease progression
- Enhances TDP-43 pathology
- May increase stress granule formation
- Modulates autophagy pathways
The ALS-risk alleles differ from SCA2 expansions but share:
- Tendency toward longer polyQ tracts
- Altered RNA binding properties
- Enhanced stress granule dynamics
Ataxin-2 is a central component of stress granules (SGs):
- Membraneless organelles formed during cellular stress
- Contain untranslated mRNAs and RNA-binding proteins
- Regulate translation during stress recovery
- Connected to autophagy and lysosomal pathways
- Implicated in ALS/FTD pathogenesis
SG dysfunction in ALS/FTD:
- Persistent SGs may become toxic
- Impaired SG clearance in disease
- Sequestration of essential proteins
SCA2 is caused by CAG repeat expansions in ATXN2 (34-200+ repeats), leading to:
-
Protein Misfolding and Aggregation
- Expanded polyQ tract causes misfolding
- Forms cytoplasmic and nuclear aggregates
- Disrupts proteostasis
-
Dysregulated RNA Metabolism
- Impaired RNA processing
- Altered translation of neuronal proteins
- Disrupted miRNA pathways
-
Selective Neuronal Vulnerability
- Degeneration of Purkinje cells
- Brainstem nuclei involvement
- Peripheral neuropathy
Ataxin-2 is a major ALS risk factor through multiple mechanisms:
-
Intermediate Repeat Expansions
- ATXN2 repeat lengths of 27-33 repeats increase ALS risk ~3-fold
- Repeat lengths >34 are fully penetrant for ALS
-
C9orf72 Interaction
- Ataxin-2 interacts with C9orf72 dipeptide repeat proteins (DPRs)
- Enhances toxicity of GGGGCC repeat expansions
- Coordinates stress granule pathology
-
Stress Granule Pathology
- Persistent stress granule formation
- Impaired SG clearance
- Sequestration of RNA and proteins
- Disrupted RNA metabolism
- ATXN2 variants associated with PD risk
- Ataxin-2 inclusions found in PD brains
- Links to alpha-synuclein pathology
- Modulates α-synuclein aggregation through RNA metabolism pathways
The expanded polyglutamine tract in ATXN2 leads to toxic gain-of-function through several interconnected mechanisms:
Ataxin-2 normally regulates multiple aspects of RNA metabolism. The expanded polyQ protein abnormally binds to RNA processing machinery, leading to:
- Altered splicing: Dysregulation of alternative splicing programs essential for neuronal function
- Impaired translation: Abnormal interaction with PABP disrupts translational control
- mRNA stability defects: Altered decay rates for transcripts encoding neuronal proteins
- miRNA processing: Disrupted small RNA biogenesis pathways
Stress granules (SGs) are membraneless organelles that form when cells encounter cellular stress. Ataxin-2 is a central scaffold protein in SG assembly:
- SG recruitment: Ataxin-2 recruits multiple RNA-binding proteins to SGs
- SG dynamics: Regulates SG assembly, maintenance, and disassembly
- mRNA triage: Coordinates mRNA fate between translation and degradation
In disease states:
- Mutant ataxin-2 forms persistent SGs that become toxic
- SGs may seed aggregation of other disease-related proteins
- Impaired SG clearance leads to proteostatic stress
- SG pathology connects to ALS, FTD, and other neurodegenerative diseases
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of ALS and FTD. Ataxin-2 interacts with C9orf72 through:
- Dipeptide repeat protein binding: Ataxin-2 binds to toxic DPRs generated from C9orf72 repeats
- SG modulation: Coordinated regulation of stress granule dynamics
- Shared pathways: Both proteins regulate RNA metabolism and autophagy
- Synergistic toxicity: Intermediate ATXN2 repeats enhance C9orf72 toxicity
Targeting ATXN2 expression offers therapeutic potential for both SCA2 and ALS:
- Antisense oligonucleotides (ASOs): Reduce mutant ATXN2 mRNA levels
- RNAi-based approaches: AAV-delivered shRNAs for long-term suppression
- CRISPR targeting: Allele-specific editing of expanded repeats
Given ataxin-2's central role in SG biology:
- SG assembly inhibitors: Prevent pathogenic SG formation
- SG clearance enhancers: Promote disassembly of persistent SGs
- mTOR inhibitors: Rapamycin and analogs to enhance autophagy
Supporting neuronal survival:
- RNA metabolism modulators: Restore normal RNA processing
- Autophagy enhancers: Improve clearance of toxic species
- Mitochondrial protectants: Support energy metabolism
Transgenic and knock-in mouse models expressing mutant ATXN2 recapitulate key disease features:
- Motor coordination deficits
- Progressive cerebellar degeneration
- Stress granule accumulation
- Age-dependent phenotype progression
Fruit fly models have been instrumental in:
- Identifying genetic modifiers of polyQ toxicity
- Testing therapeutic compounds
- Characterizing stress granule dynamics
Zebrafish provide vertebrate models for:
- Developmental studies
- High-throughput drug screening
- Live imaging of aggregate dynamics
- CAG repeat analysis for SCA2 diagnosis
- ATXN2 repeat length as ALS risk factor
- Predictive testing for at-risk family members
- Ataxin-2 protein levels in CSF
- Stress granule markers
- Neurofilament light chain (NfL)
- Physical therapy for ataxia
- Occupational therapy
- Speech therapy for dysarthria
- Monitoring for respiratory complications
- ASO-mediated silencing: Reduce mutant ataxin-2 expression
- Small molecule modulators: Stabilize normal protein conformation
- Neuroprotective agents: Support cerebellar neuron survival
- ASOs targeting ATXN2: Reduce ataxin-2 levels in motor neurons
- Stress granule modulators: Promote SG clearance
- Combination approaches: Target both ATXN2 and C9orf72 pathways
- ATXN2 repeat length as genetic risk marker
- Ataxin-2 protein levels in CSF as disease biomarker
- Stress granule markers for therapeutic response
- Ataxin-2 intermediate repeats in ALS. Neuron, 2012.
- Ataxin-2 and C9orf72 interaction in ALS/FTD. Brain, 2015.
- Ataxin-2 stress granules in neurodegeneration. Trends in Neurosciences, 2019.
- SCA2 pathogenesis and therapy. Neuromuscular Disorders, 2018.